Here, we characterize RDX8940, a novel, orally administered TGR5 agonist designed to have minimal systemic effects and investigate its activity in mice fed a Western diet, a model of NAFLD and mild insulin resistance. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.